Prostate cancer screening definition

Prostate cancer screening means medically viable methods for
Prostate cancer screening means medically viable methods
Prostate cancer screening means tests and other measures

Examples of Prostate cancer screening in a sentence

  • Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  • Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.

  • Prostate cancer screening (RCW 48.20.392, 48.21.- 227, 48.44.327, and 48.46.277).

  • Prostate cancer screening may be medically necessary for male to female transgender individuals who have retained their prostate.

  • Prostate cancer screening (RCW 48.20.392, 48.21.227, 48.44.327, and 48.46.277).

  • Prostate cancer screening for male-to-female transgender Members who have retained their prostate.

  • Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

  • Prostate cancer screening may be medically necessary for male to female trans identified persons who have retained their prostate.

  • Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y et al (2015) Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

  • Prostate cancer screening tests: Con- ditions for and limitations on coverage.

Related to Prostate cancer screening

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Animal means any nonhuman animate being endowed with the power of voluntary action.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Medical cannabis means the same as that term is defined in Section 26-61a-102.

  • sickle cell disease means a hemolytic disorder characterized by chronic anemia, painful events, and various complications due to associated tissue and organ damage; "hemolytic" refers to the destruction of the cell membrane of red blood cells resulting in the release of hemoglobin.

  • Wild animal means any mammal, bird, fish, or other creature of a wild nature endowed with sensation and the power of voluntary motion.

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Biological diversity means the variability among living organisms from all sources including, inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes of which they are part; this includes diversity within species, between species and of ecosystems.

  • Phase 1 Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of Licensed Product or that would otherwise satisfy the requirements of 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country in the Territory other than the United States.